Zacks Research Analysts Lower Earnings Estimates for Integer Holdings Co. (NYSE:ITGR)

Integer Holdings Co. (NYSE:ITGR) – Equities research analysts at Zacks Research cut their Q1 2025 EPS estimates for Integer in a report released on Thursday, April 18th. Zacks Research analyst D. Dey now anticipates that the medical equipment provider will earn $1.42 per share for the quarter, down from their prior estimate of $1.44. The consensus estimate for Integer’s current full-year earnings is $5.31 per share. Zacks Research also issued estimates for Integer’s Q2 2025 earnings at $1.41 EPS.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.05. Integer had a return on equity of 10.80% and a net margin of 5.68%. The company had revenue of $413.15 million for the quarter, compared to the consensus estimate of $409.04 million. During the same period in the previous year, the business earned $1.11 EPS. The firm’s revenue was up 10.9% compared to the same quarter last year.

A number of other research analysts also recently issued reports on ITGR. CL King initiated coverage on shares of Integer in a research report on Thursday, March 14th. They set a “buy” rating and a $137.00 target price on the stock. Benchmark increased their price objective on shares of Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. KeyCorp boosted their target price on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research report on Tuesday, April 9th. Finally, Bank of America raised Integer from a “neutral” rating to a “buy” rating and upped their price target for the stock from $105.00 to $135.00 in a research note on Monday, April 15th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $120.50.

Integer Price Performance

Shares of ITGR opened at $116.65 on Monday. The firm has a market cap of $3.91 billion, a PE ratio of 43.36, a price-to-earnings-growth ratio of 1.61 and a beta of 1.10. Integer has a 52-week low of $69.40 and a 52-week high of $121.53. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.71 and a current ratio of 2.80. The business’s 50 day moving average price is $112.03 and its two-hundred day moving average price is $99.05.

Institutional Investors Weigh In On Integer

Hedge funds and other institutional investors have recently made changes to their positions in the business. Blue Trust Inc. lifted its position in Integer by 483.3% in the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 377 shares in the last quarter. Principal Securities Inc. bought a new position in shares of Integer in the fourth quarter valued at approximately $67,000. Quadrant Capital Group LLC boosted its position in shares of Integer by 10.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock valued at $141,000 after buying an additional 132 shares during the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in shares of Integer by 66.6% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,461 shares of the medical equipment provider’s stock valued at $115,000 after buying an additional 584 shares during the last quarter. Finally, Strs Ohio grew its holdings in Integer by 54.5% during the fourth quarter. Strs Ohio now owns 1,700 shares of the medical equipment provider’s stock worth $168,000 after buying an additional 600 shares in the last quarter. 99.29% of the stock is owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.